Back to results
US 11,840,732 B2Granted
Diagnostic methods
AssigneeIscaff Pharma AB
InventorsGöran Landberg, Anders Ståhlberg, Joakim Håkansson
Life of this patent
Estimating the term…
Abstract
A method for determining one or more tumour properties in a subject with a tumour, the method comprising:—seeding a cell-free scaffold obtained from the tumour with cancer cells;—culturing the cancer cells in the scaffold;—assaying the cultured cancer cells for the presence of target molecules indicative of the expression of one or more genes in the cells; and—determining one or more tumour properties based on the results of the assay.
Claims13
A method for determining one or more properties of a tumour in a patient, the method comprising:
- seeding a 3-dimensional cell-free scaffold obtained from the tumour in the patient with cancer cells, wherein the cancer cells are not taken from the tumour in the patient;
- culturing the cancer cells in the scaffold;
- assaying the cultured cancer cells for the presence of target molecules indicative of the expression of one or more genes in the cells;
- and
- determining one or more properties of the tumour from which the 3-dimensional cell-free scaffold was obtained based on the presence of target molecules indicative of the expression of one or more genes in the cells in the assay;
- and wherein the one or more genes are selected from the group consisting of:
- ACTN1;
- AIFM1;
- ALDH2;
- ALDOA;
- ANXA1;
- AP1B1;
- AP2B1;
- ATM;
- ATXN1;
- BAG2;
- BAG3;
- BHLHE40;
- BIRC5;
- BTBD2;
- BYSL;
- C3;
- CAMK2B;
- CAMK4;
- CARD11;
- CASP3;
- CAV1;
- CEACAM1;
- CHD3;
- COL17A1;
- CRCT1;
- DAPK1;
- DMD;
- DPYSL2;
- DYSF;
- E2F1;
- EGFR;
- EIF2AK3;
- EP300;
- EPOR;
- ERBB3;
- ESR1;
- FANCC;
- FEN1;
- FHIT;
- FKBP5;
- FN1;
- FOS;
- FRMD6;
- GADD45A;
- GADD45G;
- GOLM1;
- GSN;
- GSTP1;
- HCK;
- HDAC5;
- HSPB1;
- HSPD1;
- IGF1R;
- IL4R;
- ITGA6;
- ITGB4;
- JAK1;
- JUN;
- KAT2B;
- KIF15;
- KRT18;
- KRT8;
- LYST;
- LRP1;
- LRPS;
- MAP2;
- MAP3K14;
- MAP3K5;
- MAPK3;
- MAPKAPK3;
- MST1R;
- NDRG1;
- NME1-NME2;
- NOS3;
- NPAS2;
- NPHP1;
- NQO1;
- NR3C;
- PIK3CG;
- PAEP;
- PAK1;
- PARK2;
- PARP1;
- PDE4D;
- PFN2;
- PIM1;
- PTN;
- PKD1;
- PLA2G4A;
- PLD1;
- PPARGC1A;
- PPL;
- PPM1A;
- PPP1R15A;
- PPP2R1B;
- PRKCA;
- PRNP;
- PSG9;
- PSME3;
- RABAC1;
- RAC2;
- RASA1;
- RBL1;
- RGS2;
- RPS6KA3;
- RUNX1T1;
- SH2B3;
- SH3GL3;
- SLC9A3R1;
- SMAD4;
- SNX9;
- SORBS2;
- SOX9;SP1;
- SPG7;
- SREBF1;
- STUB1;
- SUMO4;
- SVIL;
- TGFB1 11;
- TH;
- TNFAIP3;
- TNFRSF14;
- TNIK;
- TP73;
- TPD52L1;
- TRIO;
- TUBA1A;
- VIM;
- WEE1;
- XPO5;YAP1;
- and ZNF259.
134 more elements
Dependencies are inferred from the claim text.